Endometrial adenocarcinoma is staged surgically, and advanced endometrial carcinoma is considered to be FIGO stage III and IV. The Gynecologic Oncology Group (GOG) has come a long way in developing new strategies in the management of advanced endometrial carcinoma. Combining surgery, radiation, and chemotherapy, the 5-year survival has improved to between 40-60% in newly diagnosed advanced endometrial carcinoma. Recent findings in GOG184 indicate that multiple risk factors noted at the time of surgical staging could lead to concurrent clinical trials that could be completed expeditiously rather than a subsequent ten year long phase III trial including all the various risk subgroups of patients. This review is a focus on the accomplishments of the GOG in advanced endometrial carcinoma with an emphasis on future challenges.
INTRODUCTION
Endometrial adenocarcinoma is staged surgically, and advanced endometrial carcinoma is considered to be FIGO Stage III and FIGO Stage IV. Stage III patients include those with tumor invading the adnexa, uterine serosa, or pelvic and/or para-aortic nodes, as well as malignancy found in pelvic washings or upper vagina. Low risk endometrial carcinoma (FIGO Stage I) has high acceptable cure rates by surgery alone except in higher risk (FIGO Stage IC, II and early III) patients. Adjunctive trials are currently underway to establish the role of radiation and chemotherapy in such higher risk patients. By taking advantage of discoveries made in treatment of recurrence after prior therapy, advances have been made by the Gynecologic Oncology Group (GOG) in treatment of advanced endometrial carcinoma. Combining surgery, radiation and chemotherapy, the five year survival has improved to between 40-60% in newly diagnosed advanced endometrial carcinoma. Yet, recent findings in GOG184 indicate that multiple risk factors noted at the time of surgical staging could lead to concurrent clinical trials that could be completed expeditiously rather than a subsequent ten year long phase III trial including all the various risk subgroups of patients. 1 This review is a focus on the accomplishments of the Gynecologic Oncology Group (GOG) in advanced endometrial carcinoma with an emphasis on future challenges. Is it time for a different clinical trial approach?
CHEMOTHERAPY
The GOG (www.gog.org) over the past twenty years has performed prospective phase II and phase III clinical trials to identify more active regimens for advanced endometrial carcinoma treatment. Undoubtedly, progress has been made with use of radiation in combination with new, more effective chemotherapy.
Doxorubicin was the first highly active drug for endometrial carcinoma to be identified in the 1970's, but it has taken twenty years to conduct clinical trials in advanced endometrial carcinoma to assess the impact of other chemotherapy. Initially, these clinical trials were slow-going because of the reluctance to treat recurrent patients primarily with chemotherapy rather than progestin therapy. Comprehensive testing of potential chemotherapeutic agents has since been evaluated in both first and second line settings (Table 1, 2) .
Recommendations for primary chemotherapy treatment changed when survival of patients with grade 1 lesions treated with progestin therapy was no higher than 5-10%, despite an approximate 25% overall response (Table 3) .
For example, in GOG 153, the alternating dose of megestrol acetate and tamoxifen achieved a response rate of 27% and had the highest number of complete responders. Since the response rate was lower than that achieved by chemotherapy, hormonal therapy has been abandoned for GOG trials in advanced endometrial carcinoma. Exceptions for possible use of hormonal therapy in GOG trials are in purported endometrial complex hyperplasia with atypia or evaluation of new agents such as Faslodex R in GOG188.
A response rate of 30-40% can be expected with first line treatment using doxorubicin, but the survival remains low. Even so, first line testing of chemotherapy agents remains acceptable to best assess activity of new agents where survival remains low even with current three drug combination therapy. First line GOG testing has led to subsequent trials using drug combinations that have achieved improved results. In addition, first line testing has avoided use of drugs such as liposomal doxorubicin which would appear as an ideal agent with markedly reduced toxicity. Yet, in both first and second line trials, liposomal doxorubicin had low activity in the range of 10-12% for recurrent endometrial carcinoma.
RADIATION AND CHEMOTHERAPY
In the 1990's, the GOG began to explore the utility of whole abdominal radiation combined with chemotherapy for advanced endometrial carcinoma [2] [3] [4] (Table 4) . GOG 094 was successful in establishing the role of whole abdominal radiation especially for the high risk types of clear cell and papillary serous carcinoma. 5 Concurrently, in GOG 107 the combination of cisplatin and doxorubicin in a phase III trial was proven superior to doxorubicin alone in recurrent endometrial carcinoma. 6 In 1996, GOG 129C results indicated that paclitaxel was highly active as second line treatment in advanced endometrial carcinoma with a 28% overall response rate. 7 By the year 2000, in GOG 122 chemotherapy alone was noted to be superior to whole abdominal radiation. 8 Shortly thereafter, the three drug combination of doxorubicin, cisplatin and paclitaxel was noted to be superior to doxorubicin and cisplatin. 9 The GOG Final Statistical Report in January 2007 (www.gog. org) for GOG184 indicated that the addition of paclitaxel to doxorubicin and cisplatin following surgery and volume directed radiation did not increase survival. There has been no replacement yet activated for GOG184 largely because the control chemotherapy arm is unclear, and the question of how radiation and chemotherapy should be combined remains unanswered. In GOG 209, the current phase III protocol for recurrence, the combination of doxorubicin, cisplatin and 
CHALLENGES DERIVED FROM GOG184 FOR FUTURE CONSIDERATION?
Since GOG184 is the most recently concluded GOG clinical trial in advanced endometrial carcinoma, specific challenges for the future can be based on the findings of this trial. 1 The GOG Corpus Committee is charged with the responsibility of protocol development for advanced endometrial carcinoma. The statistical updates contained in the six month statistical reports, now readily available on the GOG web site, are reviewed at each six month meeting. The statistical abstracts of the study chairs that summarize the analyses of completed clinical trials are regularly reviewed by the committee members who also attend the presentation of the analyses. All of this information is used to craft a replacement protocol by the Corpus Committee which then requires approval by the GOG committee in charge of development of all GOG protocols. There must be final approval for activation by the National Cancer Institute.
Unfortunately the timeline for the last phase III protocol for advanced endometrial carcinoma (GOG 184) took 10 years. several hundred patients would be to have instant replacements activated as soon as the prior study closes for patient entry. The minimal desirable goal would be to have as short a development phase as possible. Unfortunately, there is no GOG184 Replacement (184R) protocol active yet even though GOG 184 was closed to patient entry in 2004. The endpoint for GOG184 was Recurrence Free Survival (RFS), but if the endpoint of survival had been used, GOG184 would not be closed for analysis yet. The population of patients did have a high survival of 62 and 64% for each arm which delayed the initiation of the statistical analysis for three years from the date of last patient entry. The Stage IV patients (66 patients) were barred from further entry once GOG122 was analyzed to reveal that chemotherapy was superior to radiation in advanced endometrial carcinoma. No prospective randomized trial is perfect but several questions arise when it takes so long to answer clinical questions.
During the four years of patient accrual in GOG184, 659 patients with 2 cm or less of residual endometrial carcinoma following TAH/BSO with or without node dissection received volume directed (to site of the tumor) radiation, then 552 were randomized to doxorubicin and cisplatin with or without paclitaxel. At the conclusion of the study, there was no difference in Recurrence Free Survival (RFS) with 62 and 64% survival for each arm.
FUTURE CHALLENGES
1. Should there be statistical carve outs of subgroups of the GOG184 552 eligible patients to develop the replacements of GOG184 or GOG184R's? The new GOG184R's would be modeled on the prior study with the primary objectives being to achieve results in 2-3 years rather than one result in 10 years. For example, should a GOG184R contain any low risk patients that were clearly identified in GOG184 such as most grade 1 and 2 patients who had survivals in the 90% and 70% range, respectively (Fig. 1)? 1 Should successive randomized phase II trials be designed and activated before the final results of the first trial are known? 2. Should statistical carve outs of GOG184 lead to Stage III high risk designed protocols where only grade 3, clear cell and papillary serous, gross residual disease patients, and patients with positive para-aortic nodes are included with a projected 30-60% survival range? Should high risk patients within advanced endometrial cancer patients not be the target for separate protocol development? The patients at high risk in GOG 184 included 55% (309/552) of patients in which 41% had anaplastic or grade 3 with a RFS Hazard Ratio (HR) of 3.12, 13% had serous histology with a RFS HR of 4.43, and 2% had clear cell (2%) histology with a RFS HR of 3.45 (Fig. 1) .
3. Should patients with gross disease be given the three drug combination although overall the survival between the two arms was similar? There is high likelihood although the numbers are small that the addition of paclitaxel increased survival for patients with gross residual disease in GOG184 (Fig. 2) .
1 Yet, should gross disease patients even be included in GOG184R? 4. Should full dose chemotherapy beginning with cycle one be administered with filgrastim or pegfilgrastim in all protocols as was done in GOG184, as the use of growth factor would likely be necessary to assure equidosing of chemotherapeutic agents? By making growth factor use mandatory in both arms of GOG184, there was no question that all patients received maximum dosing and afforded the use of full dose paclitaxel (160 mg/m 2 ) which clearly had no influence on overall outcome.
5. Should dose reduction of chemotherapeutic agents be based primarily on grade 1-3 neutrophil toxicity? Clinically inconsequential grade 3 neutrophil toxicity prompting automatic dose reductions was first noted early in GOG184 when the protocol was amended to include growth factor mandatorily in both arms.
6. Should extensive pelvic node dissections, as done electively in GOG184, be done since, in the 552 randomized patients, pelvic node status was not significant? Aortic node status was predictive of outcome but not pelvic node status. Rather than recommending "node dissection," should only para-aortic node sampling be encouraged or should extensive imaging of the para-aortic nodes be used to direct extended field radiation if node positive?
7. How should radiation and chemotherapy be sequenced? From GOG184, it was determined that older patients can tolerate full dose doxorubicin and cisplatin with or without paclitaxel after receiving volume directed radiation with one half receiving vaginal brachytherapy after full staging surgery. So, how should these modalities is used to maximize the most optimal outcome? 8. Is there a role for extended field radiation or vaginal brachytherapy in advanced endometrial cancer? Within GOG184, no patients were randomized to receive radiation volume directed treatment to tumor sites and the specific details of the radiation within the constraints of the protocol varied at the election of the radiation oncologist, therefore no conclusions can be reached about the effectiveness of radiation. It is possible that GOG184R may offer evaluation of radiation vs chemotherapy to finally address the need for what form of radiation in advanced endometrial carcinoma is useful.
9. Should other treatment approaches for advanced endometrial carcinoma be considered such as IP therapy, chemoradiation, or molecular targeting agents combined with chemotherapy?
10. Should clinical trials of the future for advanced endometrial carcinoma be primarily based upon the statistically significant (Hazards Regression Model) eight factors from GOG184? Stage (IV vs III), residual disease (gross vs microscopic), extended field radiation (yes vs no), histology/grade (serous vs adenocarcinoma), positive para-aortic node (yes vs no), positive cytology (yes vs no), pelvic metastases (serosa/adnexa yes or no) and age (risk increases with age) were significantly associated with RFS with the most high risk categories of clear cell/papillary serous histology and grade 3 adenocarcinoma. 1 Or should GOG184R be a duplicate ten year trial with different chemotherapy in the exact same population? 11. Is it time for a change in the huge multi-year phase III clinical trials approach for advanced endometrial carcinoma as the RFS has increased, and should replacement protocols be based on comprehensive statistical analyses and not primarily treatment outcome? Should those significant factors that clearly had impact on the outcome be the basis for several phase II and phase III trials?
CONCLUSION
The GOG has come a long way in developing new strategies in the management of advanced endometrial carcinoma. Surgery, chemotherapy and radiation have made the primary contributions to progress. Sophisticated statistical analyses are key to the understanding of the results and the basis for design of future trials. Upon reflection of all the findings of GOG184, the last trial completed by the Gynecologic Oncology Group in advanced endometrial carcinoma, a number of challenges for the future are noted in the ten questions presented here. Basically, is it worth ten years to perform one trial to answer one clinical question in advanced endometrial carcinoma which can be a widely heterogeneous group of patients?
